BioCentury This Week
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Podcasting since 2020 • 315 episodes
BioCentury This Week
Latest Episodes
Ep. 305 - FDA's Future; In Vivo CAR T Plays; Psychedelics; CDK2
The Trump administration’s overhaul of FDA is still underway, but the agency has already veered away from its decades-long trajectory in ways that will profoundly reshape medical product development and the lives of U.S. patients. On the latest...
•
Season 6
•
Episode 305
•
38:47
Ep. 304 - Syncona Reshapes Fund; Lilly's $1B Verve Bet; FDA's 2-Track Future
Publicly traded U.K. investment firm and company builder Syncona is restructuring its fund amid ongoing market challenges in the biopharma industry. On the latest BioCentury This Week podcast, BioCentury’s analysts
•
Season 6
•
Episode 304
•
35:15
Ep. 303 - Gene Therapy Safety, Amylin in Obesity & FDA's Future
The tragic death of a second non-ambulatory DMD patient treated with Sarepta's Elevidys gene therapy marks a turning point for the field and should drive all stakeholders to come together to figure out how to safely treat patients with this new...
•
Season 6
•
Episode 303
•
33:50
Ep. 302 - Takeaways from BioCentury Grand Rounds Chicago
With federal funding at risk and VCs increasingly focused on de-risked assets, academia is facing unprecedented headwinds despite rapid advancements in innovation. One potential bright spot: Pharma, which is turning to academia to access fi...
•
Season 6
•
Episode 302
•
31:05
Ep. 301 - ASCO’s First-in-Human Trials, Crossover Investors & FDA's Rare Disease Plans
Translational trends at this year’s ASCO meeting featured new and selective ways to target cell surface receptors on solid tumors. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the findings from Executive Di...
•
Season 6
•
Episode 301
•
35:59
Podcasts we love
Check out these other fine podcasts recommended by us, not an algorithm.
